1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
624A08FC516B06AC900258C75002E289E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-disease-awareness-program-oncology-structure-timing?opendocument
18
19opendocument
2018.97.14.81
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Influences on Market Entry

Disease Awareness Program Excellence in Oncology: Structure and Timing

ID: 5872


Features:

4 Info Graphics

13 Data Graphics

280+ Metrics

3 Narratives


Pages/Slides: 24


Published: 2025


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Disease Awareness Program Excellence in Oncology: Structure and Timing”

STUDY OVERVIEW

Cancer-focused awareness efforts are essential in helping patients and healthcare providers keep pace with rapidly advancing diagnostics and treatments.

However, structuring and timing these efforts within the crowded oncology space remains a challenge for many organizations.

Best Practices, LLC benchmarked leading oncology-focused organizations to understand how they are designing and sequencing their awareness programs. This study provides tactical insights and real-world examples of program structures and timing best suited for oncology education.


KEY TOPICS

  • Oncology Disease Awareness Program Structure
  • Disease Awareness Tactics
  • Timing of Disease Awareness Activities

KEY METRICS

  • Organizational structure of oncology disease awareness programs – Total benchmark class, large vs. mid-small pharma; global vs. country level; single brand vs. portfolio
  • Functional leadership and cross-team collaboration in oncology disease awareness programs
  • Prevalence of dedicated oncology disease awareness teams
  • Initiation and conclusion points of oncology disease awareness resourcing – Total benchmark class, large vs. mid-small pharma; global vs. country level; single brand vs. portfolio; highly competitive vs. less competitive market
  • Timing and utilization of oncology disease awareness activities
  • Most frequent oncology disease awareness activities

SAMPLE KEY FINDINGS

  • Structure: Manufacturers with large, single country footprints or extensive portfolios tend to default to decentralized and hybrid disease awareness structures.
  • Alliances: Advocacy groups are valuable partners to collaborate and foster relationships with, with less emphasis on giving grants / financial support.

METHODOLOGY

Best Practices, LLC engaged 11 leaders from 10 life sciences companies specializing in oncology therapies for this benchmarking research. Select executives participated in detailed operational interviews. Relevant secondary research is incorporated to enrich the analysis.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Communications; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Bayer; Daiichi Sankyo; EMD Serono; Eli Lilly and Company; Genentech; Merck KGaA; Merck Sharp & Dohme; NexGen Healthcare; Sanofi; Tokai Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.